Low molecular weight heparin in obstetric care: A review of the literature

Reproductive Sciences

Volumn 18, Issue 7, 2011, Pages 602-613

  D'Ippolito, Silvia ^a,c   Ortiz, Amparo Santamaria ^b   Veglia, Manuela ^a   Tersigni, Chiara ^a   Di Simone, Nicoletta ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

low molecular weight heparin; preeclampsia; pregnancy complications; recurrent pregnancy loss; thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PREDNISONE; PROGESTERONE;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FETUS DEATH; FETUS GROWTH; FETUS WASTAGE; GENE MUTATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; MEDLINE; OBSTETRIC CARE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; SOLUTIO PLACENTAE; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS PREVENTION;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 79959506570     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719111404612     Document Type: Review

References (61)

1. Greer IA. Antithrombotic therapy for recurrent miscarriage. N Engl J Med. 2010 ; 362 (17). 1630-1631
2. Pabinger I. Thrombophilia and its impact on pregnancy. Thromb Res. 2009 ; 123 (suppl 3). S16 - S21
3. Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol. 2004 ; 191 (2). 412-424 (Pubitemid 39178692)
4. Lussana F, Dentali F, Abbate R, et al. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2009 ; 124 (5). e19 - e25
5. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008 ; 6 (4). 632-637 (Pubitemid 351404930)
6. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000 ; 342 (6). 374-380 (Pubitemid 30084535)
7. Middeldorp S. Thrombophilia and pregnancy complications: cause or association?. J Thromb Haemost. 2007 ; 5 (suppl 1). 276-582
8. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost. 2001 ; 86 (3). 800-803 (Pubitemid 32834188)
9. Preston FE, Rosendaal FR, Walker ID, et al. EPCOT study: increased fetal loss in women with heritable thrombophilia. Lancet. 1996 ; 348 (9032). 913-916 (Pubitemid 26333847)
10. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999 ; 340 (1). 9-13 (Pubitemid 29024678)
11. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophila and adverse pregnancy outcome) A systematic review. Eur J Obstet Gynecol Reprod Biol. 2002 ; 101 (1). 6-14 (Pubitemid 34142238)
12. Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden gentype: a meta-analysis. Thromb Haemost. 2004 ; 91 (4). 700-711 (Pubitemid 38477450)
13. Mello G, Parretti E, Marozio L, et al. Thrombophilia is significantly associated with severe preeclampsia. Results of a large-scale, case-controlled study. Hypertension. 2005 ; 46 (6). 1270-1274 (Pubitemid 43189722)
14. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2005 ; 132 (2). 171-196 (Pubitemid 43381552)
15. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Trhombosis: risk and economic assessment of thrmobophilia screening (TREATS) study. Health Technol Assess. 2006 ; 10 (11). 1-110
16. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens. 2003 ; 21 (7). 1121-1128
17. Clark P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol. 2008 ; 140 (2). 236-240 (Pubitemid 350284489)
18. Silver RM, Zhao Y, Spong CY, et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol. 2010 ; 115 (1). 14-20
19. Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Edocrinol. 2003 ; 14 (1). 111
20. Wells PS, Rodger MA. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications. J Thromb Haemost. 2004 ; 2 (5). 1188-1190
21. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003 ; 101 (6). 1333-1344 (Pubitemid 36694363)
22. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992 ; 166 (5). 1318-1323
23. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 (2). 295-306
24. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007 ; 56 (7). 2382-23891
25. Nelson SM, Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update. 2008 ; 14 (6). 623-645
26. Brenner B, Hoffmann R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000 ; 83 (5). 693-697 (Pubitemid 30248516)
27. Kupferminc MJ, Fait G, Many A, et al. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypert Pregnancy. 2001 ; 20 (1). 35-44 (Pubitemid 32672926)
28. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2002 ; 1 (3). 433-438
29. Gris JC, Mares P. The long and winding road...towards LMWH for pregnancy loss. J Thromb Haemost. 2005 ; 3 (4). 224-226 (Pubitemid 41623605)
30. Gris JC, Mercier E, Querè I, et al. Low-molecular weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004 ; 103 (10). 3695-3699 (Pubitemid 38596284)
31. Grandone E, Brancaccio V, Colaizzo D, et al. Preventig adverse obstetric outcomes in women weith genetic thrombophilia. Fertil Steril. 2002 ; 78 (2). 371-375 (Pubitemid 34831739)
32. Bar J, Mashiah R, Cohen-Sacher B, et al. Effect of thromboprophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications. Thromb Res. 2001 ; 101 (4). 235-241 (Pubitemid 32206578)
33. Brenner B, Hoffmann R, Carp H, et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005 ; 3 (2). 227-229 (Pubitemid 41623606)
34. Lindqvist PG, Merlo J. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence?. Thromb Haemost. 2005 ; 3 (2). 221-223 (Pubitemid 41623604)
35. Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. BMJ. 1996 ; 313 (7057). 570-571 (Pubitemid 26293636)
36. Leduc L, Dubois E, Takser L, Rey E, David M. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007 ; 29 (10). 787-793
37. Abou-Nassar K, Kovacs MJ, Kahn SR, et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost. 2007 ; 98 (1). 163-171 (Pubitemid 47074192)
38. Isermann B, Sood R, Pawlinski R, et al. Thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003 ; 9 (3). 258-260
39. Girardi G, Redecha B, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004 ; 10 (11). 1222-1226 (Pubitemid 39540439)
40. Mousa HA, Alfirević Z. Thrombophilia and adverse pregnancy outcome. Croat Med J. 2001 ; 42 (2). 135-145 (Pubitemid 32525312)
41. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008 ; 112 (2 pt 1). 359-372
42. Greer IA, Nelson-Piercy C. Low-molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005 ; 106 (2). 401-407 (Pubitemid 40981229)
43. Management of recurrent pregnancy loss. Practice Bull. 2001 ; 24 (2). 1-12
44. Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriage. Fertil Steril. 2006 ; 86 (2). 362-366 (Pubitemid 44118966)
45. Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey AA, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet. 2008 ; 278 (1). 33-38
46. Kaandorp SP, Goddijn M, Van der Post JAM. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010 ; 362 (17). 1586-1596
47. Bose P, Black S, Kadyrov M, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol. 2005 ; 192 (1). 23-30 (Pubitemid 40164214)
48. Di Simone N, Marana R, Castellani R, et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum. 2010 ; 62 (5). 1504-1512
49. Girardi G. Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation. J Reprod Immunol. 2005 ; 66 (1). 45-51 (Pubitemid 40798126)
50. Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol. 2006 ; 133 (1). 62-67 (Pubitemid 43327199)
51. Salas A, Sans M, Soriano A, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut. 2000 ; 47 (1). 88-96
52. Schiessl B. Inflammatory response in preeclampsia. Mol Aspects Med. 2007 ; 28 (2). 210-219 (Pubitemid 46843193)
53. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005 ; 308 (5728). 1592-1594 (Pubitemid 40807500)
54. Mello G, Parretti E, Fatin C, et al. Low-molecular weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005 ; 45 (1). 86-91 (Pubitemid 40066419)
55. Ferrazzani S, D'Alessio MC, Fatigante G. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy. 2006 ; 25 (2). 115-127
56. Leach RE, Romero R, Kim YM, et al. Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Lancet. 2002 ; 360 (9341). 1215-1219 (Pubitemid 35232721)
57. Leach RE, Kilburn BA, Petkova A, Romero R, Armant DR. Diminished survival of human cytotrophoblast cells exposed to hypoxia/reoxygenation injury and associated reduction of heparin-binding epidermal growth factor-like growth factor. Am J Obstet Gynecol. 2008 ; 198 (4). 471.e1 - e7
58. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophila: a pilot randomized controlled trial. J Thromb Haemost. 2009 ; 7 (1). 58-64
59. Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low molecular weight heparin. Thromb Haemost. 2007 ; 97 (4). 505-513 (Pubitemid 46592926)
60. Lekfou E, Khamashta M, Hampson G, Hunt BJ. Low molecular weight heparin induced osteoporosis and osteoporotic fractures: a myth or existing entity?. Lupus. 2010 ; 19 (1). 3-12
61. Janiaux E, Farquarson RG, Christinasen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod. 2006 ; 21 (9). 2216-2222 (Pubitemid 44530592)